Anders Hallberg

Anders Hallberg (born 29 April 1945 in Vetlanda, Jönköping County (Småland)) is a Swedish pharmaceutical researcher, professor in medicinal chemistry and 2006–2011 Rector Magnificus and Vice Chancellor at Uppsala University.

During the twenty years that followed, he worked at the Uppsala Biomedical Center (BMC), but kept in touch with his old company, now Astra Zeneca, through an assignment as a research advisor.

One year after arriving at Uppsala, in 1991, Hallberg became Chairman of the Department of Organic Pharmaceutical Chemistry and from 1992 to 1996 he acted as Dean for Research at the Faculty of Pharmacy.

Hallberg's research interests encompass a range of protein targets of pharmaceutical relevance, including proteases and G-protein coupled receptors (GPCRs).

Compounds are optimized using computer-aided techniques and are preferentially synthesized using high-speed chemistry and robust palladium-catalyzed C-C bond forming reactions partly developed in his laboratory.

More recently, the main focus of the Drug Discovery program was to identify novel ligands that interfere with protein targets in the renin/angiotensin system (RAS).

Compound C21, (buloxibutid) now owned by Vicore Pharma AB (founded by AH et al.) has been extensively studied and is currently undergoing clinical evaluations (Phase II) with first indication idiopathic pulmonary fibrosis.

Hallberg has founded biotech companies, has > 40 patents and has authored >290 articles published in international scientific journals (number of citations >10 000).

The son, Mathias Hallberg, is Professor of Molecular research on drug dependence and Dean of the Faculty of Pharmacy at Uppsala University[8].